Objectives: Triple negative breast cancer (TNBC) is a complex and intrinsically aggressive tumour with poor prognosis, and the discovery of targeted small-molecule drugs for TNBC treatment still remains in its infancy. In this study, we aimed to discover a small-molecule agent for TNBC treatment and illuminate its potential mechanisms.
| INTRODUCTION
Triple negative breast cancer (TNBC) is a complex and intrinsically aggressive tumour characterized by lacking immunohistochemical expressions of oestrogen receptors (ER), progesterone receptors and human epidermal growth factor receptors. [1] [2] [3] It represents approximately 15%-20% of all diagnosed breast cancer patients and is highly prevalent in younger (under the age of 40) and African-American-originated women. Moreover, women diagnosed at the earliest stage of TNBC have an initial 5-year survival rate of 70%, which is lower than the 80% observed for other breast cancer subtypes. [4] [5] [6] Currently, the US FDA has not approved a standard therapy or proprietary medicine for TNBC. Chemotherapy including administering anthracyclines, taxanes or platinum to disrupt cancer cell functions, as well as radiation therapy, is the mainstay in the management of TNBC. 7 However, several difficulties such as multidrug resistance, strong systemic toxicity, rapid in vivo clearance and endosome degradation in cytosol have been encountered throughout the TNBC therapeutics. 6 Effective targeted treatment for TNBC is facing a significant clinical challenge, and the discovery of a novel targeted small-molecule drug has been emerging as the focus for the current TNBC therapeutics.
Autophagy, a term from Greek "auto" (self) and "phagy" (to eat), refers to an evolutionarily conserved cellular mechanism for the Dejuan Sun and Lingjuan Zhu contributed equally to this work.
clearance of damaged or superfluous organelles, such as endoplasmic reticulum, golgi apparatus and mitochondria. [8] [9] [10] Recent work suggests that autophagy is important in cell death decisions and can protect cells from apoptosis and caspase-independent death. 11 However, unusual levels of autophagy can also do the opposite-it can also kill cells. Autophagic cell death is known as Type II programmed cell death to distinguish it from apoptosis or Type I programmed cell death.
Although autophagic cell death and apoptosis bear distinct morphological characteristics and physiological process, there would be close connections between the regulatory machinery that control autophagy and apoptosis. [11] [12] [13] Sometimes apoptosis and autophagy could exert synergetic effect, while sometimes autophagy would be triggered only when apoptosis is suppressed. Moreover, recent studies have further pointed out that autophagy and apoptosis may be interconnected and even simultaneously regulated by the same trigger in tumour cells.
Eukaryotic elongation factor-2 kinase (eEF2K), well-known to be a Previous reports showed that Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that has been widely used to modulate the concentration of serotonin in the central nervous system. 18 It is well-known as Prozac for the treatment of depression. Actually, there is encouraging evidence demonstrating that Fluoxetine interferes with mitochondrial function and may induce cell apoptosis. 19 The researches demonstrated that breast tumour cells possess the enzymatic machinery to synthesize serotonin, which acts by an autocrine or paracrine mechanism in conjunction with other serotonergic pathway components to maintain tumour growth, seed metastases and resist cytotoxic therapies. 20 A N-methyl-D-aspartic acid (NMDA) receptor blockade by ketamine led to an inhibition of eEF2K followed by enhanced protein synthesis and potentiation of hippocampal synapses that might mediate the antidepressant response of this compound. 21, 22 In addition, the researchers stated that ketamine is metabolized in vivo to a ketamine derivative that shows antidepressant responses without blockage of NMDA receptors. The antidepressant effect of this derivative was still accompanied by a decrease in the phosphorylation of eEF2, an increase of synaptic transmission and neuronal network synchrony. 23, 24 There is encouraging evidence demonstrating that Fluoxetine interferes with mitochondrial function and may changes autophagic flux and apoptosis.
So, we choose Fluoxetine as candidate small molecule. In this study, we reported a small molecule, Fluoxetine that potently inhibits cell proliferation, associated with autophagy and apoptosis and inhibition of eEF2K.
These findings highlight Fluoxetine that has the potential to impact the future TNBC therapy. 
| MATERIALS AND METHODS

| Cell culture and reagents
eEF2 (#2332), p-eEF2 thr56 (#2331), AMPKα (#5831), p-AMPKα thr172 (#5256), mTOR (#2983), p-mTOR ser2448 (#2971), p70S6K (#2708), p-p70S6K ser389 (#9234), ULK1 (#8054), p-ULK1 ser317 (#12753), p- ULK1 ser555 (#5869), mATG13 (#13273), Atg101 (#13492), FIP200 (#12436), Beclin-1 (#3495), p62 (#8025), LC3B (#3868),
| Cell viability assay
Cells were dispensed in 96-well plates at a density of 5 × 10 4 cells/mL. 
| Transmission electron microscopy
The ultra-structure of cytoplasmic vacuolization was observed using a Philips Tecnai-12 Biotwin transmission electron microscope similar to previous reports. 25 Briefly, collected cells were fixed with 2% glutaraldehyde for 2 hours, washed with PBS and then post-fixed with 1% OsO 4 for 1.5 hours at 4°C. The samples were then washed and dehydrated with graded alcohol. After dehydration, the samples were infiltrated and embedded in 618 epoxy resin. Ultrathin sections were cut, stained with uranyl acetate and lead citrate and then examined under the transmission electron microscope (Hitachi 7000, Hitachi, Japan). 
| GFP-LC3 transfection and monodansylcadaverine staining assays
| Apoptosis assay
| Western blot analysis
Western blot analysis was carried out by the method as previous description. 26 Cells were treated with Fluoxetine for indicated times. 
| iTRAQ assay and network analysis
| Functional clustering analysis
Functional clustering was determined using the DAVID functional annotation tool (http://david.abcc.ncifcrf.gov/). 28 The functional categories used were GO term related to Biological Process and Molecular
Function. The conforming differentially expressed proteins were used as the background set. And, the protein synthesis-and programmed cell death-related proteins were shown in further network analysis.
| Statistical analysis
All the presented data and results were confirmed in at least 3 independent experiments. The data are expressed as means ± SD and statistical comparisons were made by 1-way ANOVA and Student's t test of SPSS 17.0 (Chicago, IL, USA). P < .05 was considered statistically significant.
| RESULTS
| Fluoxetine induces autophagy in MDA-MB-231 and MDA-MB-436 cells
The effect of Fluoxetine on cell viability was determined on 6 breast Figure 1C ).
Monodansylcadaverine, a probe for the detection of autophagic vacuoles, was applied to Fluoxetine-treated cells, and the green fluorescent dots were observed and photographed under fluorescence microscopy ( Figure 1D ). To further confirm that Fluoxetine induces autophagy, we found that treatment with Fluoxetine resulted in a time-dependent elevation of LC3-II, which is a marker of autophagy, and increased expression of Beclin-1; both of these proteins are important markers of autophagy. Moreover, the level of the selective autophagy substrate, p62/SQSTM1, was reduced by treatment with Fluoxetine ( Figure 1E ). Next, we added the lysosomal inhibitor, bafilomycin A1 (BafA1), to validate the existence of autophagic flux. The results showed that LC3-II and p62/SQSTM1 significantly accumulated in the presence of BafA1, indicating that autophagic flux is enhanced by treatment with Fluoxetine ( Figure 1F ). These results collectively suggest that Fluoxetine can induce autophagy in breast cancer cells.
| Fluoxetine induces autophagy through eEF2K inhibition and activation of AMPK-mTOR-ULK complex pathway
To illuminate the mechanism for Fluoxetine-induced autophagy, we examined the expression of autophagy-associated proteins. Firstly, we found that Fluoxetine significantly decreased the phosphorylation of eEF2K at ser 78 and ser 398 , indicating the inhibition of eEF2K
activity. In addition, we also found that Fluoxetine inhibited the phosphorylation of eEF2 at thr 56 and had little effect on eEF2 expression, suggesting the activation of eEF2 caused by eEF2K inhibition ( Figure 2A ). To further demonstrate whether Fluoxetine has Fluoxetine alone treatment, using Fluoxetine in combination with eEF2K siRNA resulted in more potent effect on these protein expressions ( Figure 2B ). As AMPK plays a key role in the regulation of energy homeostasis and eEF2K is regulated by the mTOR-p70S6K pathway, we subsequently examined the expression of AMPK, mTOR and p70S6K. These results showed that after treatment with Fluoxetine, the phosphorylation of mTOR and p70S6K decreased, while AMPK was activated, suggesting that Fluoxetine may regulate autophagy through the AMPK and mTOR pathways ( Figure 2C ). Because the ULK1-mAtg13-FIP200 complex is closely related with autophagosome formation, we next examined the expression levels of ULK1, mAtg13, Atg101 and FIP200. As a result, the expression levels of p-ULK1 (phosphorylation at ser 317 and ser 555 ), mAtg13, Atg101 and FIP200 increased in a time-dependent manner after treatment with Fluoxetine ( Figure 2D ). Taken ) and LC3 were examined by Western blot analysis. C, Fluoxetine affected the AMPK-mTOR-p70S6K pathway. After treatment, the expression levels of AMPK, p-AMPK, mTOR, p-mTOR, p70S6K and p-p70S6K were examined by Western blot analysis. D, Fluoxetine activated the ULK complex. After treatment, the expression of the ULK complex was examined by Western blot analysis. β-actin was used as a loading control
| Fluoxetine induces autophagic cell death in MDA-MB-231 and MDA-MB-436 cells
To determine the role of autophagy induced by Fluoxetine, the autophagy inhibitor 3-methyladenine (3-MA), which inhibits autophagy by blocking autophagosome formation via inhibiting type III phosphatidylinositol 3-kinases (PI3KIII), was employed to block the induction of autophagy. The MTT assay was carried out to assess the cell viability. We found that the cell viabilities were significantly increased following treatment with 2 mmol/L 3-MA (P < .01) ( Figure 3A) . 
| Fluoxetine induces apoptosis in MDA-MB-231 and MDA-MB-436 cells
To determine the mechanism of Fluoxetine-induced cell death, we employed flow cytometry analysis with PI staining to detect the occurrence of apoptosis. The results suggested that Fluoxetine-induced apoptosis in MDA-MB-231 and MDA-MB-468 cells, which was determined by the increasing percentage of cells in sub-G1 phase ( Figure 4A,B) . Moreover, Western blot analysis revealed that the expression levels of caspase-3/8 and PARP were remarkably upregulated after Fluoxetine treatment ( Figure 4C ). Taken together, these results indicate that Fluoxetine could induce apoptosis in MDA-MB-231 and MDA-MB-468 cells.
| The intricate relationship between Fluoxetineinduced autophagic cell death and apoptosis
To explore the intricate relationship between Fluoxetine-induced autophagic cell death and apoptosis, we next added pan-caspase inhibitor selected for further analysis. Given the pivotal role that eEF2K plays in protein translation elongation and programmed cell death, proteins that were differentially expressed in iTRAQ analysis and that were associated with both protein synthesis and programmed cell death were considered highly relevant to the mechanisms with Fluoxetine.
Moreover, functional annotation and clustering were processed in both cell lines ( Figure 6A ).
We also built the global human PPI network and modified this network into the eEF2K-related PPI network. Then, we identified differentially expressed proteins that interacted with eEF2K in this network (Tables S1 and S2 ). Four differential expression proteins, BIRC6, SNAP29, Bif-1 and BNIP1, were predicted to interact with eEF2K or to be affected by eEF2K ( Figure 6B ). Next, we found that BIRC6 was down-regulated, while SNAP29, BNIP1 and Bif-1 were up-regulated after Fluoxetine treatment in MDA-MB-231 cells ( Figure 6C ). To further validate the possible mechanisms under eEF2K inhibition, we used eEF2K siRNA to compare with Fluoxetine.
Interestingly, we found that Fluoxetine displayed almost coordinative effects with eEF2K siRNA on the expressions of novel eEF2K population. *P < .05; **P < .01; ***P < .001 compared with control group. C, The expression levels of apoptosis-related proteins, including Caspase 3, Caspase 8 and PARP were examined by Western blot analysis. β-actin was used as a loading control interactors. When Fluoxetine was used in combination with eEF2K siRNA, we found more markedly decreased expression of BIRC6, as well as up-regulation of SNAP29, BNIP1 and Bif-1 ( Figure 6D ).
These results indicate that the Fluoxetine-induced mechanism is involved BIRC6, BNIP1, SNAP29 and Bif-1, which may be associated with inhibition of eEF2K.
| DISCUSSIONS
Triple negative breast cancer constitutes a heterogeneous subtype of breast cancers characterized by its biological aggressiveness, worse prognosis and lacking of therapeutic targets. A majority of TNBC patients still exhibit poor outcomes, with only 30%-45% of patients Then the expression levels of BNIP1, SNAP29, Bif-1 and BIRC6 were examined by Western blot analysis. β-actin was used as a loading control achieving a pathological complete response (pCR) and survival rates similar to other breast cancer subtypes. Consequently, TNBC remains a significant challenge for the current TNBC therapeutics. Previous studies have demonstrated that Fluoxetine treatment changes autophagic flux and apoptosis, and the PI3K-AKT-mTOR regulatory pathway is involved in the mechanism of Fluoxetine. 29 In our study, we demonstrated that Fluoxetine could induce autophagic cell death in TNBC cells. Interestingly, we found that the autophagy-modulating mechanism of Fluoxetine was dependent on the AMPK-mTOR-ULK complex pathways. A recent study has revealed that silencing eEF2K induced AMPK-ULK1-dependent autophagy in colon cancer cells, suggesting eEF2K can regulate ULK1 indirectly. 30 And it is also well-known that ULK1 and ULK complex, as the initiator of autophagy, are regulated by AMPK and mTOR. 31 Therefore, Fluoxetine-induced eEF2K inhibition may lead to a feedback regulation on AMPK-mTOR-p70S6K pathways, thereby activating ULK complex to induce autophagy. Distinct from these above-mentioned mechanisms, our study also identified some novel key proteins such as BINP1, SNAP29, Bif-1 and BIRC6, which could be associated with eEF2K in Fluoxetine-induced autophagic cell death. BNIP1 is capable of recruiting autophagy receptor p62, which simultaneously binds both ubiquitin and LC3 to link ubiquitination and autophagy. 32 And recent evidence suggests that SNAP29 is essential for the fusion between autophagosomes and lysosomes controlled by Atg14/Atg14L. 33 Bif-1, a membrane curvature-inducing protein, interacts with Beclin-1 through UVRAG and regulates the post-Golgi trafficking of membrane-integrated Atg9a for autophagy. 34 BIRC6, as an inhibitor of apoptosis, has recently shown to be overexpressed in different types of cancer such as breast cancer. 35 Among these proteins, Bif-1 and BNIP1 exert significant roles in both autophagy and apoptosis, whereas SNAP29 is necessary to autophagosome maturation and BIRC6 is very important to inhibit apoptosis. Our findings would uncover more potential mechanisms for Fluoxetine-induced autophagic cell death, which remain to be further investigated.
In conclusion, our results demonstrate that a small molecule, Fluoxetine, potently inhibits tumour growth of TNBC, as well as inducing apoptosis and autophagic cell death associated with inhibition of eEF2K, modulation of multiple signalling pathways, including AMPKmTOR-ULK, BIRC6, BNIP1, SNAP29 and Bif-1, which may provide a promising avenue for future TNBC therapy.
CONFLICTS OF INTEREST
We declare that none of the authors have financial interest related to this work.
ORCID
Lixia Chen
http://orcid.org/0000-0003-2196-1428
